iPS cells

Using lentiviral vectors ensures high efficiency transduction producing higher quality iPS cells with the correct phenotype prior to differentiation.

Customer projects

Vectalys is involved in a collaborative research project called Ship In. The aim of this project is the development  of standard protocols to obtain iPS cells :

  • From highly purified Integrating Lentiviral Vectors (ILVs)
  • From Non Integrating Lentiviral Vectors (NILVs)
  • On different parental cells: fibroblasts, keratinocytes, blood cells...

 

Why Vectalys lentiviral vectors?

Vectalys specific serum free purified vectors batches (C) for primary and stem cells transduction shows the following advantages:

  • Vectalys reprogramming lentiviral vectors ensures around 90% transduction efficiency at very low M.O.I. (between 2 and 5), with one transduction only.
  • The Vectalys patented lentiviral vectors do not affect the viability and the proliferation of your target cells.
  • Vectalys reprogramming lentiviral vectors enable a higher quality iPS clones compared to the conventional protocol.
  • Vectalys highly concentrated lentiviral vectors enable to manage the M.O.I. to reprogramme iPS from hardly permissive and delicate cells.

 

At Vectalys, we provide full teams of experts in cells engineering to support you and to fit the best your projects. We will help you to design the best experimental protocol for your gene delivery project.

Publications

  • Rashid S. T, Corbineau S, Hannan N, Marciniak S.J, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas D. A, Vallier L. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest., 2010, 120 (9), 3127-3136.
  • Lapillonne H, Kobari L, Mazurier C, Tropel P, Giarratana M-C, Zanella-Cleon I, Kiger L, Wattenhofer-Donze M, Puccio H, Hebert N, Francina A, Andreu G, Viville S, and Douay L. Red blood cells generation from human induced pluripotent stem cells: perspectives for transfusion medicine. Haematologica. 2010, 95 (10), 1651-1659.
  • Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev., 2009, 23: 2134-2139.